NCT02148250View on ClinicalTrials.gov

PK/PD Study of U-500 Regular Insulin

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Type 2 DiabetesInsulin ResistanceHigh Insulin Requirements
Interventions
DRUG

U-500 insulin, 100 syringe units

Subjects are randomized to receive 100 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.

DRUG

U-500 insulin, 200 syringe units

Subjects are randomized to receive 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

University of Minnesota

OTHER

NCT02148250 - PK/PD Study of U-500 Regular Insulin | Biotech Hunter | Biotech Hunter